The proapoptotic F-box protein Fbxl7 regulates mitochondrial function by mediating the ubiquitylation and proteasomal degradation of survivin

Journal of Biological Chemistry

Volumn 290, Issue 19, 2015, Pages 11843-11852

  Liu, Yuan ^a   Lear, Travis ^a   Iannone, Olivia ^a   Shiva, Sruti ^b   Corey, Catherine ^b   Rajbhandari, Shristi ^a   Jerome, Jacob ^a   Chen, Bill B ^a   Mallampalli, Rama K ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; FLUORINE; MITOCHONDRIA; MOBILE SECURITY;

CARBONYLCYANIDE M CHLOROPHENYLHYDRAZONE; CARBOXYL-TERMINAL; CELLULAR EXPRESSION; INHIBITOR OF APOPTOSIS; MITOCHONDRIAL FUNCTION; OXIDATIVE PHOSPHORYLATION; POLYUBIQUITYLATION; PROTEASOMAL DEGRADATION;

PROTEINS;

LYSINE; PROTEIN FBXL7; REGULATOR PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; BIRC5 PROTEIN, HUMAN; BIRC5 PROTEIN, MOUSE; F BOX PROTEIN; FBL6 PROTEIN, HUMAN; FBXL7 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; PROTEASOME; REPRESSOR PROTEIN; UBIQUITIN;

ALPHA HELIX; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UBIQUITINATION; WILD TYPE; ANIMAL; APOPTOSIS; ENERGY METABOLISM; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; METABOLISM; MOUSE; MUTATION; PROTEIN SECONDARY STRUCTURE;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; ENERGY METABOLISM; F-BOX PROTEINS; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MITOCHONDRIA; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, SECONDARY; REPRESSOR PROTEINS; UBIQUITIN; UBIQUITINATION;

EID: 84929012256     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.629931     Document Type: Article

References (41)

1. Ashkenazi, A., and Dixit, V. M. (1998) Death receptors: signaling and modulation. Science 281, 1305-1308
2. Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., and Green, D. R. (2010) The BCL-2 family reunion. Mol. Cell 37, 299-310
3. Salvesen, G. S., and Duckett, C. S. (2002) IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 3, 401-410
4. Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C., and Altieri, D. C. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-584
5. Altieri, D. C. (2003) Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3, 46-54
6. Tamm, I., Richter, S., Oltersdorf, D., Creutzig, U., Harbott, J., Scholz, F., Karawajew, L., Ludwig, W. D., and Wuchter, C. (2004) High expression levels of X-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin. Cancer Res. 10, 3737-3744
7. Gazzaniga, P., Gradilone, A., Giuliani, L., Gandini, O., Silvestri, I., Nofroni, I., Saccani, G., Frati, L., and Aglianò, A. M. (2003) Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann. Oncol. 14, 85-90
8. Cao, C., Mu, Y., Hallahan, D. E., and Lu, B. (2004) XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23, 7047-7052
9. Hagenbuchner, J., Kuznetsov, A. V., Obexer, P., and Ausserlechner, M. J. (2013) BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene 32, 4748-4757
10. Ambrosini, G., Adida, C., and Altieri, D. C. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917-921
11. Li, Z., Pei, X. H., Yan, J., Yan, F., Cappell, K. M., Whitehurst, A. W., and Xiong, Y. (2014) CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrity. Mol. Cell 54, 805-819
12. Arora, V., Cheung, H. H., Plenchette, S., Micali, O. C., Liston, P., and Korneluk, R. G. (2007) Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J. Biol. Chem. 282, 26202-26209
13. Hershko, A., and Ciechanover, A. (1998) The ubiquitin system. Annu. Rev. Biochem. 67, 425-479
14. Deshaies, R. J., and Joazeiro, C. A. (2009) RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78, 399-434
15. Cardozo, T., and Pagano, M. (2004) The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 5, 739-751
16. Skaar, J. R., Pagan, J. K., and Pagano, M. (2013) Mechanisms and function of substrate recruitment by F-box proteins. Nat. Rev. Mol. Cell Biol. 14, 369-381
17. Wang, Z., Liu, P., Inuzuka, H., and Wei, W. (2014) Roles of F-box proteins in cancer. Nat. Rev. Cancer 14, 233-247
18. Weathington, N. M., and Mallampalli, R. K. (2014) Emerging therapies targeting the ubiquitin proteasome system in cancer. J. Clin. Invest. 124, 6-12
19. Cenciarelli, C., Chiaur, D. S., Guardavaccaro, D., Parks, W., Vidal, M., and Pagano, M. (1999) Identification of a family of human F-box proteins. Curr. Biol. 9, 1177-1179
20. Coon, T. A., Glasser, J. R., Mallampalli, R. K., and Chen, B. B. (2012) Novel E3 ligase component FBXL7 ubiquitinates and degrades Aurora A, causing mitotic arrest. Cell Cycle 11, 721-729
21. Liu, Y., Lear, T., Zhao, Y., Zhao, J., Zou, C., Chen, B. B., and Mallampalli, R. K. (2015) F-box protein Fbxl18 mediates polyubiquitylation and proteasomal degradation of the pro-apoptotic SCF subunit Fbxl7. Cell Death Dis. 6, e1630
22. Zhao, J., Wei, J., Mialki, R. K., Mallampalli, D. F., Chen, B. B., Coon, T., Zou, C., Mallampalli, R. K., and Zhao, Y. (2012) F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat. Immunol. 13, 651-658
23. Chen, B. B., Coon, T. A., Glasser, J. R., McVerry, B. J., Zhao, J., Zhao, Y., Zou, C., Ellis, B., Sciurba, F. C., Zhang, Y., and Mallampalli, R. K. (2013) A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation. Nat. Immunol. 14, 470-479
24. Wu, L., Grigoryan, A. V., Li, Y., Hao, B., Pagano, M., and Cardozo, T. J. (2012) Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem. Biol. 19, 1515-1524
25. Chan, C. H., Morrow, J. K., Li, C. F., Gao, Y., Jin, G., Moten, A., Stagg, L. J., Ladbury, J. E., Cai, Z., Xu, D., Logothetis, C. J., Hung, M. C., Zhang, S., and Lin, H. K. (2013) Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154, 556-568
26. Rico-Bautista, E., Yang, C. C., Lu, L., Roth, G. P., and Wolf, D. A. (2010) Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMCBiol. 8, 153
27. Blees, J. S., Bokesch, H. R., Rübsamen, D., Schulz, K., Milke, L., Bajer, M. M., Gustafson, K. R., Henrich, C. J., McMahon, J. B., Colburn, N. H., Schmid, T., and Brüne, B. (2012) Erioflorin stabilizes the tumor suppressor Pdcd4 by inhibiting its interaction with the E3-ligase β-TrCP1. PLoS ONE 7, e46567
28. Skaar, J. R., Pagan, J. K., and Pagano, M. (2014) SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov. 13, 889-903
29. Miller, L. K. (1999) An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. 9, 323-328
30. Bertrand, M. J., Milutinovic, S., Dickson, K. M., Ho, W. C., Boudreault, A., Durkin, J., Gillard, J. W., Jaquith, J. B., Morris, S. J., and Barker, P. A. (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30, 689-700
31. Verdecia, M. A., Huang, H., Dutil, E., Kaiser, D. A., Hunter, T., and Noel, J. P. (2000) Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct. Biol. 7, 602-608
32. Welcker, M., Singer, J., Loeb, K. R., Grim, J., Bloecher, A., Gurien-West, M., Clurman, B. E., and Roberts, J. M. (2003) Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol. Cell 12, 381-392
33. Kuchay, S., Duan, S., Schenkein, E., Peschiaroli, A., Saraf, A., Florens, L., Washburn, M. P., and Pagano, M. (2013) FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade. Nat. Cell Biol. 15, 472-480
34. Yoshida, Y., Chiba, T., Tokunaga, F., Kawasaki, H., Iwai, K., Suzuki, T., Ito, Y., Matsuoka, K., Yoshida, M., Tanaka, K., and Tai, T. (2002) E3 ubiquitin ligase that recognizes sugar chains. Nature 418, 438-442
35. Yoshida, Y., Tokunaga, F., Chiba, T., Iwai, K., Tanaka, K., and Tai, T. (2003) Fbs2 is a new member of the E3 ubiquitin ligase family that recognizes sugar chains. J. Biol. Chem. 278, 43877-43884
36. Zou, C., Chen, Y., Smith, R. M., Snavely, C., Li, J., Coon, T. A., Chen, B. B., Zhao, Y., and Mallampalli, R. K. (2013) SCF(Fbxw15) mediates histone acetyltransferase binding to origin recognition complex (HBO1) ubiquitin-proteasomal degradation to regulate cell proliferation. J. Biol. Chem. 288, 6306-6316
37. Wheatley, S. P., Henzing, A. J., Dodson, H., Khaled, W., and Earnshaw, W. C. (2004) Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo. J. Biol. Chem. 279, 5655-5660
38. Wang, H., Holloway, M. P., Ma, L., Cooper, Z. A., Riolo, M., Samkari, A., Elenitoba-Johnson, K. S., Chin, Y. E., and Altura, R. A. (2010) Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J. Biol. Chem. 285, 36129-36137
39. Fulda, S., and Vucic, D. (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 11, 109-124
40. Infante, J. R., Dees, E. C., Olszanski, A. J., Dhuria, S. V., Sen, S., Cameron, S., and Cohen, R. B. (2014) Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 32, 3103-3110
41. Cai, Q., Sun, H., Peng, Y., Lu, J., Nikolovska-Coleska, Z., McEachern, D., Liu, L., Qiu, S., Yang, C. Y., Miller, R., Yi, H., Zhang, T., Sun, D., Kang, S., Guo, M., Leopold, L., Yang, D., and Wang, S. (2011) A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J. Med. Chem. 54, 2714-2726